ストックスクリーナーアプリを入手
0.6174
1.38%
0.0084
アフターアワーズ：
.60
-0.0174
-2.82%
前日終値:
$0.609
開ける：
$0.671
24時間の取引高:
31,422
Relative Volume:
0.04
時価総額：
$800.28K
収益：
-
当期純損益:
$-21.33M
株価収益率:
-0.00543
EPS:
-113.7479
ネットキャッシュフロー:
$-9.12M
1週間 パフォーマンス:
+1.51%
1か月 パフォーマンス:
-42.83%
6か月 パフォーマンス:
-72.44%
1年 パフォーマンス:
-91.66%
1日の値動き範囲:
$0.5907
$0.671
1週間の範囲:
$0.58
$0.671
52週間の値動き範囲:
$0.58
$8.046
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
名前
Zyversa Therapeutics Inc
セクター
電話
908-370-5102
住所
217 W. MAIN STREET, SOMERVILLE
ZVSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZVSA
Zyversa Therapeutics Inc
|
0.6174 | 800.28K | 0 | -21.33M | -9.12M | -113.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Zyversa Therapeutics Inc (ZVSA) 最新ニュース
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline By Investing.com - Investing.com South Africa
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline - Investing.com Australia
Virtu Financial LLC Purchases Shares of 25,259 ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) - Defense World
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Slashes Annual Losses by 90% While Pushing Forward With Crucial Kidney Disease Drug Trial - Stock Titan
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World
ZVSA stock touches 52-week low at $0.69 amid market challenges - Investing.com Australia
ZVSA stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis - Defense World
ZyVersa’s IC 100 shows promise in OAC treatment study By Investing.com - Investing.com Australia
ZyVersa’s IC 100 shows promise in OAC treatment study - Investing.com India
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association ... - The Bakersfield Californian
ZyVersa Therapeutics Highlights Data Published in the - GlobeNewswire
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - TradingView
Breakthrough: New Drug Could Transform 50% Survival Rate in Obesity Heart Disease - Stock Titan
ZyVersa Therapeutics (ZVSA) Expected to Announce Earnings on Monday - Defense World
Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Declines By 54.6% - Defense World
ZVSA stock touches 52-week low at $0.8 amid sharp annual decline - Investing.com Australia
ZVSA stock touches 52-week low at $0.8 amid sharp annual decline By Investing.com - Investing.com South Africa
ZyVersa’s Alzheimer’s treatment shows promise in studies By Investing.com - Investing.com Australia
ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition - TipRanks
ZyVersa’s Alzheimer’s treatment shows promise in studies - Investing.com India
ZyVersa Therapeutics Highlights Data Demonstrating - GlobeNewswire
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model - The Manila Times
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model - GlobeNewswire
Breakthrough: ZyVersa's New Alzheimer's Treatment Targets Brain Inflammation With Promising Results - Stock Titan
ZyVersa secures $2 million in funding for drug development By Investing.com - Investing.com Canada
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market - GlobeNewswire
ZyVersa Therapeutics announces pricing of $2M private placement - MSN
ZyVersa secures $2 million in funding for drug development - Investing.com
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times
Healthcare Fund Backs ZyVersa With $2M Investment: Key Terms Revealed - StockTitan
ZVSA stock plunges to 52-week low, touches $0.94 amid market challenges - Investing.com Canada
ZVSA stock plunges to 52-week low, touches $0.94 amid market challenges By Investing.com - Investing.com South Africa
Wall Street Set to Open on Flat Note Wednesday as Investors Look for Signs of Tariff Relief - TradingView
ZyVersa’s IC 100 shows promise in heart failure treatment By Investing.com - Investing.com South Africa
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Di - The Manila Times
ZyVersa’s IC 100 shows promise in heart failure treatment - Investing.com
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
Major Gestational Diabetes Market Trend 2025-2034: Advancements In Diagnostic Solutions For Early Detection... - WhaTech
Larchmont broker accused of years-long insider trading scheme - Westfair Online
Biodexa Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:BDRX - Benzinga
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga
Focal Segmental Glomerulosclerosis Market Expected to rise, 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara - Barchart
Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Rises By 1,291.0% - Defense World
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Significant Decrease in Short Interest - Defense World
Blaize Debuts on NASDAQ: First AI IPO of 2025 Hits $1.2B Valuation in Historic SPAC Deal - StockTitan
2024 Research Report: Global Celiac Disease Treatment - GlobeNewswire
Zyversa Therapeutics Inc (ZVSA) 財務データ
収益
当期純利益
現金流量
EPS
10.70%
大文字化:
|
ボリューム (24 時間):